Jakafi (Ruxolitinib)
No side effects…my life is truly back - Ben Minuk
.jpg)
image by: Medication - MHML
HWN Suggests
The Jakafi Report
This is by no means a scientifically controlled study. The results were derived from an MPNforum Magazine on-line request for first hand responses from the early adopters of Jakafi. This qualitative study supplements scientific reports with fresh testimony from the patient pioneers in this revolutionary MF treatment. (Jakafi is the first drug approved by the FDA and EHA to treat myelofibrosis therapeutically and the drug that clinically demonstrated the efficacy of kinase inhibition.)
Featured
Jakafi (ruxolitinib) – Treatment of Myelofibrosis
Jakafi (ruxolitinib) is an oral janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis. It was developed by Incyte Corp in collaboration with Novartis.
Previously Featured
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Similar to myelofibrosis and essential thrombocythemia, polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm.
Resources
ChemoCare
For the treatment of intermediate and high risk myelofibrosis. For the treatment of acute graft-versus-host (GVHD) not responsive steroids, in adults and pediatric patients 12 years of older.
Jakafi
For the treatment of intermediate and high risk myelofibrosis. For the treatment of acute graft-versus-host (GVHD) not responsive steroids, in adults and pediatric patients 12 years of older.
GoodRx
Jakafi (Ruxolitinib) is an expensive drug that targets proteins in cells and stops them from growing. It is used to treat myelofibrosis and polycythemia vera. It is slightly more popular than comparable drugs.
OncoLink
Ruxolitinib is a type of targeted therapy called a kinase inhibitor. A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control different phases of cell growth. By blocking a particular enzyme from working, this medication can slow the growth of cancer cells. Ruxolitinib targets Janus Associated Kinases, JAK1, and JAK2.
